Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo
Obesity · 2024
DOI: 10.1002/oby.24030 ↗At a glance
Randomisierte kontrollierte Studie in Obesity, 2024. Written by Yuqian Bao and 3 co-authors. Institution: Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai…. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Glycemic Control, Blood Glucose. 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Eli Lilly and Company.
Abstract (original language)
Objective
The study objective was to characterize subgroups of Asia‐Pacific patients with type 2 diabetes who achieved different glycated hemoglobin (HbA1c) targets on tirzepatide treatment.
Methods
This was a post hoc analysis of the SURPASS AP‐Combo study. Baseline characteristics, changes in metabolic markers, and safety were compared between tirzepatide‐treated patients achieving HbA1c
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China.
- Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
ORCID profiles: Linong Ji
Funding
- Eli Lilly and Company
Cite
APA
Bao, Y., Han, L., Du, L., & Ji, L. (2024). Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity. https://doi.org/10.1002/oby.24030
Vancouver
Bao Y, Han L, Du L, Ji L. Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo. Obesity. 2024. doi:10.1002/oby.24030
BibTeX
@article{Bao2024,
author = {Bao, Yuqian and Han, Lin and Du, Liying and Ji, Linong},
title = {Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo},
journal = {Obesity},
year = {2024},
doi = {10.1002/oby.24030}
}
EUVIMED